/
Services-home health care services company · DE · FY ends Jan · Revenue $2.52B · 9.26% margin
$9.69
$0.21 (-2.12%)
EOD Jul 17, 2026
10.54% operating margin is respectable but not wide. ROIC at 14.08%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 20.2%, still solid. Margins contracted 3.4pp, which offsets some of the top-line progress.
ROIC dropped from 19.92% to 14.08%, capital efficiency is deteriorating. Operating margin contracted 3.4pp YoY, cost discipline may be slipping.
8.0x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$2.52B
▲ +20.2% YoY
Net Income (TTM)
$261M
▲ +2159.1% YoY
Op. Margin
9.26%
▼ -3.4pp YoY
ROIC
12.73%
▼ -5.8pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
$139M
▲ +285.6% YoY
Net Debt
$1.15B
Cash & Equiv.
$189M
5Y CAGR: +10.2%
Continue Research
At a P/E of 8.0, Aveanna Healthcare Holdings (AVAH)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Aveanna Healthcare Holdings scores 42/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Aveanna Healthcare Holdings scores 42 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 9.3% operating margin and a 12.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh AVAH's valuation and scores 42/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.